Identification

Name
Vortioxetine
Accession Number
DB09068  (DB05700)
Type
Small Molecule
Groups
Approved, Investigational
Description

Vortioxetine is an atypical antipsychotic and antidepressant indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.

Structure
Thumb
Synonyms
  • Vortioxetina
  • Vortioxétine
  • vortioxetinum
External IDs
Lu AA21004 / Lu-AA21004 / LuAA21004
Product Ingredients
IngredientUNIICASInChI Key
Vortioxetine hydrobromideTKS641KOAY960203-27-4VNGRUFUIHGGOOM-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BrintellixTablet, film coated5 mg/1OralTakeda2013-10-02Not applicableUs
BrintellixTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2015-06-052018-06-09Us
BrintellixTablet, film coated15 mg/1OralTakeda2013-10-02Not applicableUs
BrintellixTablet, film coated10 mg/1OralTakeda2013-10-02Not applicableUs64764 0560 30 nlmimage10 5a3a2d71
BrintellixTablet, film coated20 mg/1OralTakeda2013-10-02Not applicableUs
TrintellixTablet10 mgOralLundbeck Inc.2014-10-28Not applicableCanada
TrintellixTablet, film coated10 mg/1OralTakeda2013-10-02Not applicableUs
TrintellixTablet15 mgOralLundbeck Inc.Not applicableNot applicableCanada
TrintellixTablet5 mgOralLundbeck Inc.2014-10-28Not applicableCanada
TrintellixTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2016-06-202018-06-13Us
Categories
UNII
3O2K1S3WQV
CAS number
508233-74-7
Weight
Average: 298.45
Monoisotopic: 298.15036989
Chemical Formula
C18H22N2S
InChI Key
YQNWZWMKLDQSAC-UHFFFAOYSA-N
InChI
InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
IUPAC Name
1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine
SMILES
CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1

Pharmacology

Indication

Vortioxetine is indicated for the treatment of major depressive disorder (MDD).

Associated Conditions
Pharmacodynamics

Vortioxetine binds with high affinity to the human serotonin transporter (Ki=1.6 nM), but not to the norepinephrine (Ki=113 nM) or dopamine (Ki>1000 nM) transporters. Vortioxetine potently and selectively inhibits reuptake of serotonin by inhibition of the serotonin transporter (IC50=5.4 nM). Specifically, vortioxetine binds to 5­HT3 (Ki=3.7 nM), 5­HT1A (Ki=15 nM), 5­HT7 (Ki=19 nM), 5­HT1D (Ki=54 nM), and 5­HT1B (Ki=33 nM), receptors and is a 5­HT3, 5­HT1D, and 5­HT7 receptor antagonist, 5­HT1B receptor partial agonist, and 5­HT1A receptor agonist.

Mechanism of action

Vortioxetine is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, while also acting as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
A5-hydroxytryptamine receptor 3A
antagonist
Human
A5-hydroxytryptamine receptor 7
antagonist
Human
A5-hydroxytryptamine receptor 1B
partial agonist
Human
A5-hydroxytryptamine receptor 1A
agonist
Human
UBeta-1 adrenergic receptor
ligand
Human
Usolute carrier family 6 member 2
blocker
Human
Absorption

The maximal plasma vortioxetine concentration (Cmax) after dosing is reached within 7 to 11 hours postdose. Absolute bioavailability is 75%. No effect of food on the pharmacokinetics was observed.

Volume of distribution

The apparent volume of distribution of vortioxetine is approximately 2600 L, indicating extensive extravascular distribution.

Protein binding

The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations. No apparent difference in the plasma protein binding between healthy subjects and subjects with hepatic (mild, moderate) or renal (mild, moderate, severe, ESRD) impairment is observed.

Metabolism

Vortioxetine is extensively metabolized primarily through oxidation via cytochrome P450 isozymes CYP2D6, CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8 and CYP2B6 and subsequent glucuronic acid conjugation. CYP2D6 is the primary enzyme catalyzing the metabolism of vortioxetine to its major, pharmacologically inactive, carboxylic acid metabolite, and poor metabolizers of CYP2D6 have approximately twice the vortioxetine plasma concentration of extensive metabolizers.

Route of elimination

Following a single oral dose of [14C]­labeled vortioxetine, approximately 59% and 26% of the administered radioactivity was recovered in the urine and feces, respectively as metabolites. Negligible amounts of unchanged vortioxetine were excreted in the urine up to 48 hours.

Half life

Mean terminal half­life is approximately 66 hours

Clearance
Not Available
Toxicity

The most commonly reported adverse effects during clinical trials were nausea, diarrhea, and dry mouth. The FDA label includes a blackbox warning for the following risks and complications: serotonin syndrome, especially when combined with other serotonergic agents; increased risk of abnormal bleeding, especially when combined with NSAIDs, aspirin, or other drugs that affect coagulation; activation of mania/hypomania; hyponatremia; and suicidal thoughts and behaviour in children, adolescents, and young adults.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vortioxetine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Vortioxetine can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Vortioxetine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Vortioxetine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vortioxetine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Vortioxetine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Vortioxetine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vortioxetine.Approved, Investigational
AlaproclateAlaproclate may increase the serotonergic activities of Vortioxetine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Vortioxetine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Vortioxetine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Almotriptan.Approved, Investigational
AlosetronAlosetron may increase the serotonergic activities of Vortioxetine.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Vortioxetine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vortioxetine.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Vortioxetine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vortioxetine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vortioxetine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Vortioxetine.Experimental
AmphetamineThe metabolism of Vortioxetine can be decreased when combined with Amphetamine.Approved, Illicit, Investigational
ApalutamideThe serum concentration of Vortioxetine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineVortioxetine may increase the hypotensive activities of Apomorphine.Approved, Investigational
AprepitantThe serum concentration of Vortioxetine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vortioxetine.Approved, Investigational
ArmodafinilThe metabolism of Vortioxetine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Vortioxetine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Vortioxetine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Vortioxetine.Approved
AtazanavirThe metabolism of Vortioxetine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Vortioxetine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Azaperone.Investigational, Vet Approved
AzelastineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Vortioxetine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Vortioxetine.Illicit
BenmoxinThe metabolism of Vortioxetine can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Vortioxetine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Vortioxetine.Approved
BetaxololThe metabolism of Vortioxetine can be decreased when combined with Betaxolol.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Bifeprunox.Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Vortioxetine.Investigational
BoceprevirThe metabolism of Vortioxetine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Vortioxetine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vortioxetine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
BrofaromineThe metabolism of Vortioxetine can be decreased when combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vortioxetine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Bromisoval.Experimental
BromocriptineBromocriptine may increase the vasoconstricting activities of Vortioxetine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Vortioxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Vortioxetine.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vortioxetine.Approved, Investigational
BuprenorphineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Vortioxetine.Approved
BuspironeBuspirone may increase the serotonergic activities of Vortioxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vortioxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Vortioxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butamben.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Vortioxetine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Vortioxetine.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the vasoconstricting activities of Vortioxetine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Vortioxetine.Investigational
CapecitabineThe metabolism of Vortioxetine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe serum concentration of Vortioxetine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vortioxetine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Vortioxetine.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vortioxetine.Approved
CaroxazoneThe metabolism of Vortioxetine can be decreased when combined with Caroxazone.Withdrawn
CelecoxibThe metabolism of Vortioxetine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Vortioxetine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Vortioxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vortioxetine.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Vortioxetine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vortioxetine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Vortioxetine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vortioxetine.Approved
ChloroquineThe metabolism of Vortioxetine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vortioxetine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Vortioxetine.Experimental
ChlorpromazineThe metabolism of Vortioxetine can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vortioxetine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vortioxetine.Approved
CholecalciferolThe metabolism of Vortioxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Vortioxetine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Vortioxetine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vortioxetine.Approved, Vet Approved
CitalopramCitalopram may increase the serotonergic activities of Vortioxetine.Approved
ClarithromycinThe metabolism of Vortioxetine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Vortioxetine can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Vortioxetine.Approved
ClobazamThe metabolism of Vortioxetine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Vortioxetine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Vortioxetine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Vortioxetine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clopenthixol.Experimental
ClopidogrelThe metabolism of Vortioxetine can be decreased when combined with Clopidogrel.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vortioxetine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Vortioxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Vortioxetine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Vortioxetine can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Vortioxetine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Vortioxetine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Vortioxetine.Approved, Investigational
CrisaboroleThe metabolism of Vortioxetine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Vortioxetine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Vortioxetine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Vortioxetine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Vortioxetine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Vortioxetine.Approved
DabrafenibThe serum concentration of Vortioxetine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Vortioxetine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vortioxetine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vortioxetine.Investigational
DarifenacinThe metabolism of Vortioxetine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Vortioxetine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Vortioxetine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Vortioxetine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Vortioxetine can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Vortioxetine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Vortioxetine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vortioxetine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Vortioxetine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vortioxetine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vortioxetine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Vortioxetine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Vortioxetine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Vortioxetine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Vortioxetine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Vortioxetine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vortioxetine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Vortioxetine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Vortioxetine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vortioxetine.Experimental, Illicit
DiltiazemThe metabolism of Vortioxetine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vortioxetine.Approved
DiphenhydramineThe metabolism of Vortioxetine can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Vortioxetine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dixyrazine.Experimental
DolasetronDolasetron may increase the serotonergic activities of Vortioxetine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Vortioxetine can be increased when it is combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Doxepin.Approved, Investigational
DoxorubicinThe metabolism of Vortioxetine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Vortioxetine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Vortioxetine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Illicit
DronedaroneThe metabolism of Vortioxetine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Vortioxetine.Experimental, Illicit
DroxidopaVortioxetine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Vortioxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Vortioxetine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Vortioxetine can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Eletriptan.Approved, Investigational
EliglustatThe metabolism of Vortioxetine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Vortioxetine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Vortioxetine.Approved, Investigational
EnzalutamideThe serum concentration of Vortioxetine can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Vortioxetine.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Vortioxetine.Approved
ErgotamineErgotamine may increase the vasoconstricting activities of Vortioxetine.Approved
ErythromycinThe metabolism of Vortioxetine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the serotonergic activities of Vortioxetine.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Vortioxetine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Vortioxetine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Vortioxetine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vortioxetine.Approved, Investigational
EthanolVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vortioxetine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vortioxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vortioxetine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vortioxetine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Vortioxetine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Vortioxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Vortioxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Vortioxetine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Vortioxetine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Vortioxetine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Vortioxetine.Illicit, Vet Approved
EtravirineThe metabolism of Vortioxetine can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Vortioxetine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Vortioxetine.Approved
FelodipineThe metabolism of Vortioxetine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vortioxetine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Vortioxetine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Vortioxetine.Approved, Investigational
FloxuridineThe metabolism of Vortioxetine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Vortioxetine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vortioxetine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Vortioxetine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Vortioxetine.Approved, Illicit
FluorouracilThe metabolism of Vortioxetine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vortioxetine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vortioxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vortioxetine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vortioxetine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Vortioxetine.Approved
FluvastatinThe metabolism of Vortioxetine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Vortioxetine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Vortioxetine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vortioxetine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Vortioxetine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Vortioxetine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe metabolism of Vortioxetine can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Vortioxetine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vortioxetine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Vortioxetine.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Vortioxetine.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Vortioxetine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Vortioxetine.Approved, Illicit
GranisetronGranisetron may increase the serotonergic activities of Vortioxetine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vortioxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Vortioxetine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Vortioxetine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Vortioxetine.Approved, Vet Approved
HarmalineThe metabolism of Vortioxetine can be decreased when combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Vortioxetine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vortioxetine.Approved
HydracarbazineThe metabolism of Vortioxetine can be decreased when combined with Hydracarbazine.Experimental
HydrocodoneVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Vortioxetine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
IdelalisibThe metabolism of Vortioxetine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Iloperidone.Approved
ImatinibThe metabolism of Vortioxetine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Imipramine.Approved
IndalpineIndalpine may increase the serotonergic activities of Vortioxetine.Investigational, Withdrawn
IndinavirThe metabolism of Vortioxetine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Indiplon.Investigational
IproclozideThe metabolism of Vortioxetine can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Vortioxetine can be decreased when combined with Iproniazid.Withdrawn
IrbesartanThe metabolism of Vortioxetine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Vortioxetine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Vortioxetine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Vortioxetine can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Vortioxetine.Approved, Vet Approved
IsoniazidThe metabolism of Vortioxetine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Vortioxetine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Vortioxetine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Vortioxetine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vortioxetine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vortioxetine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Vortioxetine.Approved, Investigational
KetoconazoleThe metabolism of Vortioxetine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Vortioxetine.Approved, Nutraceutical, Withdrawn
LamotrigineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Vortioxetine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Vortioxetine can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Vortioxetine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Vortioxetine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vortioxetine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Vortioxetine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Vortioxetine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Vortioxetine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Vortioxetine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Vortioxetine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Linezolid.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lithium.Approved
LobeglitazoneThe metabolism of Vortioxetine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Vortioxetine can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Vortioxetine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Vortioxetine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vortioxetine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Vortioxetine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Vortioxetine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Vortioxetine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Vortioxetine.Approved
LuliconazoleThe serum concentration of Vortioxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Vortioxetine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Vortioxetine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Vortioxetine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Vortioxetine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Maprotiline.Approved, Investigational
MebanazineThe metabolism of Vortioxetine can be decreased when combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Vortioxetine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Vortioxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vortioxetine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vortioxetine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vortioxetine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vortioxetine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Vortioxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vortioxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Vortioxetine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vortioxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Vortioxetine.Approved
MethotrimeprazineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vortioxetine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vortioxetine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Vortioxetine.Experimental
Methylene blueThe metabolism of Vortioxetine can be decreased when combined with Methylene blue.Approved, Investigational
MethylergometrineMethylergometrine may increase the vasoconstricting activities of Vortioxetine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vortioxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Metoclopramide.Approved, Investigational
MetoprololThe metabolism of Vortioxetine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineVortioxetine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Vortioxetine.Approved, Illicit
MidostaurinThe serum concentration of Vortioxetine can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Vortioxetine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the serotonergic activities of Vortioxetine.Approved, Investigational
MinaprineThe metabolism of Vortioxetine can be decreased when combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Investigational
MirabegronThe metabolism of Vortioxetine can be decreased when combined with Mirabegron.Approved
MirtazapineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Vortioxetine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Vortioxetine can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Vortioxetine can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Vortioxetine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Vortioxetine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Vortioxetine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Mosapramine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Vortioxetine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Naratriptan.Approved, Investigational
NefazodoneThe metabolism of Vortioxetine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Vortioxetine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Vortioxetine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Vortioxetine can be decreased when it is combined with Nevirapine.Approved
NialamideThe metabolism of Vortioxetine can be decreased when combined with Nialamide.Withdrawn
NicardipineThe metabolism of Vortioxetine can be decreased when combined with Nicardipine.Approved, Investigational
NicotineThe metabolism of Vortioxetine can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Vortioxetine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vortioxetine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Vortioxetine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Nortriptyline.Approved
OctamoxinThe metabolism of Vortioxetine can be decreased when combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vortioxetine.Approved, Investigational
OlaparibThe metabolism of Vortioxetine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vortioxetine.Approved
OmeprazoleThe metabolism of Vortioxetine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Vortioxetine.Approved
OpiumThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Opium.Approved, Illicit
OrphenadrineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Vortioxetine.Investigational
OsimertinibThe serum concentration of Vortioxetine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vortioxetine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vortioxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Vortioxetine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vortioxetine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Vortioxetine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Vortioxetine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Vortioxetine.Approved, Investigational
PanobinostatThe serum concentration of Vortioxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Vortioxetine can be decreased when combined with Pantoprazole.Approved
ParaldehydeVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe metabolism of Vortioxetine can be decreased when combined with Pargyline.Approved
ParoxetineThe serum concentration of Vortioxetine can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vortioxetine.Approved, Vet Approved
PentobarbitalThe serum concentration of Vortioxetine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Vortioxetine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Vortioxetine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vortioxetine.Approved
PethidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Phenazocine.Experimental
PhenelzineThe metabolism of Vortioxetine can be decreased when combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Phenibut.Experimental
PheniprazineThe metabolism of Vortioxetine can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe serum concentration of Vortioxetine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe metabolism of Vortioxetine can be decreased when combined with Phenoxypropazine.Withdrawn
PhenytoinThe serum concentration of Vortioxetine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Vortioxetine.Approved
PioglitazoneThe metabolism of Vortioxetine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Piritramide.Approved, Investigational
PirlindoleThe metabolism of Vortioxetine can be decreased when combined with Pirlindole.Approved
PitolisantThe serum concentration of Vortioxetine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe metabolism of Vortioxetine can be decreased when combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Vortioxetine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Vortioxetine.Approved
PosaconazoleThe metabolism of Vortioxetine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleVortioxetine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Vortioxetine.Approved, Illicit
PregabalinThe therapeutic efficacy of Vortioxetine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Vortioxetine.Approved
PrimidoneThe serum concentration of Vortioxetine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe metabolism of Vortioxetine can be decreased when combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe metabolism of Vortioxetine can be decreased when combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vortioxetine.Approved, Vet Approved
PromazineThe metabolism of Vortioxetine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vortioxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Propericiazine.Approved, Investigational
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Vortioxetine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Vortioxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Vortioxetine.Investigational
PyrimethamineThe metabolism of Vortioxetine can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe serum concentration of Vortioxetine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vortioxetine.Approved
QuinidineThe serum concentration of Vortioxetine can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Vortioxetine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Quinisocaine.Experimental
RabeprazoleThe metabolism of Vortioxetine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Vortioxetine.Approved, Investigational
RanolazineThe metabolism of Vortioxetine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe metabolism of Vortioxetine can be decreased when combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vortioxetine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vortioxetine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Vortioxetine.Approved, Investigational
RifabutinThe serum concentration of Vortioxetine can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Vortioxetine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Vortioxetine can be decreased when it is combined with Rifapentine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Vortioxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Vortioxetine can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Vortioxetine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Romifidine.Vet Approved
RopiniroleVortioxetine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vortioxetine.Approved
RosiglitazoneThe metabolism of Vortioxetine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineVortioxetine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Vortioxetine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Vortioxetine.Approved
SafrazineThe metabolism of Vortioxetine can be decreased when combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Vortioxetine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Vortioxetine can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vortioxetine.Approved, Investigational
SecobarbitalThe metabolism of Vortioxetine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Vortioxetine can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Vortioxetine.Approved, Investigational, Withdrawn
SertralineSertraline may increase the serotonergic activities of Vortioxetine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vortioxetine.Approved, Vet Approved
SildenafilThe metabolism of Vortioxetine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Vortioxetine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Vortioxetine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
SorafenibThe metabolism of Vortioxetine can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Vortioxetine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Vortioxetine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine.Approved, Investigational
SulfadiazineThe metabolism of Vortioxetine can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Vortioxetine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Vortioxetine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vortioxetine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Sumatriptan.Approved, Investigational
SuvorexantVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Vortioxetine.Approved, Investigational
TamoxifenThe metabolism of Vortioxetine can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Vortioxetine.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Vortioxetine.Approved
TelaprevirThe metabolism of Vortioxetine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Vortioxetine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Vortioxetine.Approved, Investigational
TerbinafineThe serum concentration of Vortioxetine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Vortioxetine can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Vortioxetine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Vortioxetine.Investigational
ThalidomideVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vortioxetine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Vortioxetine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Vortioxetine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Vortioxetine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Vortioxetine can be increased when it is combined with Thioridazine.Approved, Withdrawn
ThiotepaThe metabolism of Vortioxetine can be decreased when combined with Thiotepa.Approved, Investigational
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vortioxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Vortioxetine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Vortioxetine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Vortioxetine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tilidine.Experimental
TipranavirThe serum concentration of Vortioxetine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vortioxetine.Approved, Investigational
TocilizumabThe serum concentration of Vortioxetine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Vortioxetine can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vortioxetine.Approved, Withdrawn
ToloxatoneThe metabolism of Vortioxetine can be decreased when combined with Toloxatone.Approved
TopiramateThe metabolism of Vortioxetine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Vortioxetine can be decreased when combined with Topiroxostat.Approved, Investigational
TramadolVortioxetine may decrease the analgesic activities of Tramadol.Approved, Investigational
TranylcypromineThe metabolism of Vortioxetine can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Vortioxetine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Vortioxetine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vortioxetine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vortioxetine.Approved, Vet Approved
TrimethoprimThe metabolism of Vortioxetine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Vortioxetine.Approved
TropisetronTropisetron may increase the serotonergic activities of Vortioxetine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Vortioxetine.Approved, Investigational
ValsartanThe metabolism of Vortioxetine can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vortioxetine.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Vortioxetine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Veralipride.Experimental
VerapamilThe metabolism of Vortioxetine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Vortioxetine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Vortioxetine.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Vortioxetine can be decreased when combined with Voriconazole.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Vortioxetine can be decreased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Vortioxetine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vortioxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Vortioxetine.Approved
ZimelidineZimelidine may increase the serotonergic activities of Vortioxetine.Withdrawn
ZiprasidoneThe metabolism of Vortioxetine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zolmitriptan.Approved, Investigational
ZolpidemVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vortioxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Vortioxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Vortioxetine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vortioxetine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]
  2. Stenkrona P, Halldin C, Lundberg J: 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013 Oct;23(10):1190-8. doi: 10.1016/j.euroneuro.2013.01.002. Epub 2013 Feb 18. [PubMed:23428337]
  3. Mork A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C: Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013 Apr;105:41-50. doi: 10.1016/j.pbb.2013.01.019. Epub 2013 Feb 1. [PubMed:23380522]
  4. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
External Links
KEGG Drug
D10184
PubChem Compound
71768094
PubChem Substance
310265001
ChemSpider
8141643
BindingDB
50400902
ChEBI
76016
ChEMBL
CHEMBL2104993
PharmGKB
PA166122595
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vortioxetine
ATC Codes
N06AX26 — Vortioxetine
AHFS Codes
  • 28:16.04.24 — Serotonin Modulators
FDA label
Download (749 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentCoronary Artery Disease / Major Depressive Disorder (MDD)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedOtherHealthy Adult Participants1
1CompletedTreatmentDepression1
1CompletedTreatmentHealthy Men1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentSevere Hepatic Impairment1
2CompletedTreatmentAnxiety Disorders / Depressive Disorders1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
2CompletedTreatmentMajor Depressive Disorder (MDD)4
2RecruitingTreatmentBinge Eating Disorder (BED)1
2, 3CompletedTreatmentMajor Depressive Disorder (MDD)1
2, 3Not Yet RecruitingOtherCognitive Change / Major Depressive Disorder (MDD)1
2, 3Not Yet RecruitingTreatmentAnxiety Disorders / Anxiety States / Cannabis Use Disorders / Depression / Pharmacotherapy1
3Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentGeneralized Anxiety Disorder (GAD)5
3CompletedTreatmentMajor Depressive Disorder (MDD)22
3CompletedTreatmentTreatment Outcomes1
3Enrolling by InvitationTreatmentMajor Depressive Disorder (MDD)2
3RecruitingTreatmentMajor Depressive Disorder (MDD)2
3WithdrawnTreatmentMajor Depressive Disorder (MDD) / Tbi1
4Active Not RecruitingTreatmentHealthy Volunteers1
4Active Not RecruitingTreatmentMajor Depressive Disorder (MDD) / Social Anxiety Disorder (SAD)1
4CompletedTreatmentDepression / Menopausal Hot Flushes / Menopause / Sleep / Vasomotor Disturbance1
4CompletedTreatmentMajor Depressive Disorder (MDD)2
4CompletedTreatmentPanic Disorders1
4Not Yet RecruitingDiagnosticMajor Depressive Disorder (MDD)1
4RecruitingBasic ScienceDepression / Depressive Disorders / Major Depressive Disorder (MDD) / Unipolar Depression1
4RecruitingOtherMajor Depressive Disorder (MDD)1
4RecruitingTreatmentAge-Related Cognitive Decline1
4RecruitingTreatmentMajor Depressive Disorder (MDD)2
4RecruitingTreatmentNegative Symptoms / Schizophrenic Disorders1
4RecruitingTreatmentPost-Traumatic Stress Disorder (PTSD)1
4WithdrawnTreatmentStage I, II or III Breast Cancer / Unipolar Major Depression1
Not AvailableRecruitingNot AvailableMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
TabletOral10 mg
TabletOral15 mg
TabletOral20 mg
TabletOral5 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8476279No2002-10-022022-10-02Us
US7144884No2003-01-092023-01-09Us
US8969355No2007-06-152027-06-15Us
US9227946No2007-06-152027-06-15Us
US8722684No2011-06-302031-06-30Us
US9861630No2007-06-152027-06-15Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00362 mg/mLALOGPS
logP4.51ALOGPS
logP4.76ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)8.85ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area15.27 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity94.01 m3·mol-1ChemAxon
Polarizability34.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]
  2. Kamei K, Maeda N, Nomura K, Shibata M, Katsuragi-Ogino R, Koyama M, Nakajima M, Inoue T, Ohno T, Tatsuoka T: Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan. Bioorg Med Chem. 2006 Mar 15;14(6):1978-92. doi: 10.1016/j.bmc.2005.10.046. Epub 2005 Nov 14. [PubMed:16290165]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Ligand
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]
7. solute carrier family 6 member 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Blocker
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396]

Drug created on May 12, 2015 11:03 / Updated on June 19, 2018 10:50